INTRODUCTION
============

Statins are essential for patients with acute myocardial infarction (AMI). Current guidelines recommend early initiation of statin therapy in statin-naïve patients with AMI unless there is a contraindication to statins.[@B1][@B2][@B3][@B4] Although many clinical studies support the initiation of statin therapy before discharge after AMI, few studies indicate the optimal timing of statin initiation in statin-naïve patients with AMI.[@B5][@B6][@B7][@B8][@B9] While the current guidelines recommend that statin therapy be started as early as possible after admission, the optimal timing of statin initiation in patients with AMI is still unknown. The timing of statin initiation varied among these studies, and several meta-analyses and large-sized observational cohort studies showed no correlation between early statin initiation and improved clinical outcomes among AMI patients.[@B10][@B11]

In the present study, we aimed to determine whether early statin initiation could reduce long-term clinical adverse events in statin-naïve AMI patients using a large, multi-center Korean registry.

METHODS
=======

Study population
----------------

The Convergent Registry of Catholic and Chonnam University for AMI (COREA-AMI) is a prospective, multi-center, web-based observational cohort registry. It was designed to reflect real-world practice as it pertains to Korean AMI patients registered at nine centres with facilities for primary percutaneous coronary intervention (PCI) representing two universities between January 2004 and December 2009.[@B12][@B13] We selected 3,921 statin-naïve patients undergoing successful PCI from among 4,748 consecutive AMI patients in the COREA-AMI registry. The exclusion criteria were as follows: in-hospital death (n=116), patients who were not prescribed a statin at discharge (n=613), patients with no data regarding statin initiation time (n=3), and patients who had already taken a statin before admission (n=95). Based on prior studies, subjects were divided into three groups according to the timing of statin initiation after admission: group 1 (statin initiation \<24 hours, n=2,665), group 2 (24--48 hours, n=480) and group 3 (≥48 hours, n=776).[@B5][@B6][@B7][@B9] We also generated three stratified models according to the timing of statin initiation to reduce bias: model 1 (\<24 hours vs. ≥24 hours), model 2 (\<48 hours vs. ≥48 hours) and model 3 (\<24 hours vs. 24--48 hours). The study protocols were approved by the ethics committee at each participating center and adhered to the principles of the Declaration of Helsinki. This registry has been registered on ClinicalTrials.gov (study ID: [NCT02385682](http://clinicaltrials.gov/ct2/show/NCT02385682)). All patients provided written informed consent for participation in the registry. Trained study coordinators at each center collected data according to a standardised format. Standardised definitions of all variables were determined by the steering committee board of COREA-AMI.

Study definitions
-----------------

The diagnosis of AMI was based on the criteria for a third universal definition of myocardial infarction (MI). Chronic kidney disease was defined as a glomerular filtration rate below 60 mL/min/1.73 m^2^, or when the patient had already received renal replacement therapy. Laboratory data were obtained on admission, except for lipid profiles; these were obtained after at least 9 hours of fasting, within 24 hours of hospitalisation. The baseline left ventricular ejection fraction (LVEF) was measured by two-dimensional echocardiography before or immediately after PCI. The timing of statin initiation, medications, and use of coronary stents, thrombi aspiration, intravascular ultrasound, and intra-aortic balloon pumps were at the operators\' discretion. All patients underwent PCI within 48 hours after admission. The extent of coronary blood flow before and after PCI was graded using the thrombolysis in myocardial infarction (TIMI) flow grade, and the complexity of coronary lesions was based on the definitions of the American College of Cardiology (ACC)/American Heart Association (AHA). Patients who underwent PCI received 300 mg aspirin and 300 or 600 mg clopidogrel as a loading dose prior to PCI. Unfractionated heparin (50--70 U/kg) was given before or during PCI to maintain the activated clotting time at 250--300 seconds. After PCI, 100--300 mg aspirin and 75 mg clopidogrel daily were prescribed as the maintenance dose.

Study endpoints
---------------

The primary endpoint was major adverse cardiac events (MACE; including cardiac death, non-fatal spontaneous MI and target-vessel revascularization \[TVR\]) during a median follow-up period of 3.8 years (interquartile range: 2.6--5.1 years). We also analysed the incidence of all-cause death, cardiac death, nonfatal spontaneous MI, target-lesion revascularisation (TLR), TVR, non-TVR, stroke, and definite or probable stent thrombosis. Nonfatal spontaneous MI was defined as the development of recurrent angina symptoms accompanied by changes in the 12-lead electrocardiogram, or increased levels of cardiac-specific biomarkers. TLR was defined as PCI for restenosis or other lesion complications within the treated segment 5 mm proximal and 5 mm distal to the stent. TVR was defined as repeated PCI for any segment of the entire coronary artery proximal and distal to the target lesion. Stent thrombosis was defined as definite and probable stent thrombosis, according to the Academic Research Consortium\'s definition.[@B14]

Patient outcomes were recorded at 1, 6, and 12 months, and annually thereafter at hospital visits or via telephone contact. Briefly, all clinical outcomes of interest were confirmed by source documents and were centrally adjudicated by the local events committee of the Cardiovascular Center, Seoul St Mary\'s Hospital, and by an independent group of clinicians who were unaware of patient status. Information about death was matched with records from the National Population Registry of the Korea National Statistical Office using a unique personal identification number to validate mortality follow-up data.[@B12]

Statistical analysis
--------------------

Continuous variables are presented as means±standard deviation (SD) and were compared using the unpaired t-test if the data were normally distributed. Non-normally distributed continuous data are summarised as medians with interquartile ranges and compared using the Mann-Whitney rank-sum test. Comparisons among the three groups were performed using one-way analysis of variance. Discrete variables are expressed as counts with percentages and were analysed by the Pearson χ^2^ test or Fisher\'s exact test. We constructed Kaplan-Meier curves to compare primary endpoints between the different statin initiation timing groups in each propensity-matched model (models 1, 2 and 3); the differences were assessed using the log-rank test. Cox\'s proportional hazards regression model (with adjustment for covariates) was used to assess clinical outcomes. Variables significant for end-points in the univariate analysis (p\<0.05) were included in the multivariate analysis. The following variables were included in the multivariate Cox regression analysis: age ≥65 years, male gender, hypertension, diabetes mellitus, chronic kidney disease, Killip class ≥3, peak level of troponin-I, glucose level, high-sensitivity C-reactive protein (hsCRP) level, LVEF, use of an angiotensin-converting enzyme inhibitor or angiotensin-II receptor blocker, multivessel disease, ACC/AHA B2/C lesion, coronary stenting, total number of stents, total stent length, mean stent diameter, periprocedural shock, ventricular tachycardia or fibrillation, and use of intra-aortic balloon pump. The propensity score was estimated by logistic regression analysis using the variable shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}.[@B15] The Hosmer-Lemeshow goodness-of-fit p value was 0.185 in model 1, 0.357 in model 2 and 0.119 in model 3. The C-statistic values for the logistic models were 0.637 in model 1, 0.635 in model 2 and 0.660 in model 3. Finally, we performed 1:1 propensity score-matching without replacement using the nearest neighbour method. A calliper width of 0.1 SD was used for matching. Data and standardized mean differences before and after matching were presented in the [Supplementary Tables 1](#S1){ref-type="supplementary-material"}, [2](#S2){ref-type="supplementary-material"}, [3](#S3){ref-type="supplementary-material"}, [4](#S4){ref-type="supplementary-material"}, [5](#S5){ref-type="supplementary-material"}, [6](#S6){ref-type="supplementary-material"}. The value of standardized mean differences was within 0.1 in nearly all variables of 3 models (0.103 in ST-segment elevation myocardial infarction \[STEMI\] and 0.144 in creatine kinase-myocardial band isozyme after matching of model 3).

###### Baseline clinical characteristics

![](kcj-49-419-i001)

  Variables                  Time from admission to statin initiation (hours)   p value                                                       
  -------------------------- -------------------------------------------------- -------------------- ------------------- -------------------- ---------
  Demographics                                                                                                                                
                             Age (years)                                        61.4±12.5            61.9±12.1           63.3±12.5            0.001
                             Male                                               1,993 (74.8)         354 (73.8)          531 (68.4)           0.001
  Initial vital signs                                                                                                                         
                             Systolic blood pressure (mmHg)                     130.8±28.8           129.7±27.4          127.3±30.3           0.012
                             Heart rate (/minute)                               75.9±18.4            75.7±18.4           76.7±20.6            0.523
  Medical history                                                                                                                             
                             Current or ex-smoking                              1,564 (58.7)         297 (61.9)          419 (54.0)           0.061
                             Hypertension                                       1,264 (47.4)         240 (50.0)          410 (52.8)           0.007
                             Diabetes mellitus                                  791 (29.7)           151 (31.5)          254 (32.7)           0.091
                             Familial history of coronary artery disease        153 (5.7)            28 (5.8)            42 (5.4)             0.760
                             Chronic kidney disease                             83 (3.1)             16 (3.3)            33 (4.3)             0.134
                             Cerebrovascular accident                           114 (4.3)            16 (3.3)            39 (5.0)             0.530
                             Previous myocardial infarction                     100 (3.8)            14 (2.9)            30 (3.9)             0.947
                             Previous PCI                                       105 (3.9)            16 (3.3)            30 (3.9)             0.816
  STEMI                      1,739 (65.3)                                       255 (53.1)           426 (54.9)          \<0.001              
  Killip class ≥3            223 (8.4)                                          38 (7.9)             107 (13.8)          \<0.001              
  Laboratory findings                                                                                                                         
                             Serum creatinine (mg/dL)                           0.96 (0.80--1.16)    1.00 (0.80--1.20)   1.00 (0.80--1.20)    0.080
                             Peak level of troponin-I (mg/dL)                   25.0 (5.1--50.0)     13.5 (4.2--50.0)    16.4 (3.9--50.0)     0.374
                             Peak level of CK-MB (mg/dL)                        60.6 (14.8--161.1)   27.7 (10.8--92.4)   36.8 (11.2--115.6)   \<0.001
                             Total cholesterol (mg/dL)                          180 (155--207)       185 (159--205)      181 (157--208)       0.286
                             Triglyceride (mg/dL)                               102 (70--148)        111 (75--156)       108 (76--145)        0.061
                             HDL-cholesterol (mg/dL)                            42 (36--49)          41 (36--49)         41 (35--48)          0.065
                             LDL-cholesterol (mg/dL)                            115 (94--140)        120 (99--140)       116 (96--141)        0.167
                             Serum glucose (mg/dL)                              145 (118--191)       144 (112--194)      150 (119--207)       0.066
                             NT pro BNP (pg/mL)                                 492 (110--1,672)     551 (154--1,559)    849 (198--2,947)     0.001
                             High-sensitivity CRP (mg/L)                        5.6 (1.7--20.1)      6.5 (2.1--26.5)     9.3 (2.9--31.6)      \<0.001
  LVEF (%)                   53.9±11.1                                          56.1±11.8            53.1±11.7           \<0.001              
  Medications at discharge                                                                                                                    
                             Aspirin                                            2,664 (100)          475 (99.0)          776 (100)            0.336
                             Clopidogrel                                        2,656 (99.7)         480 (100)           773 (99.6)           0.937
                             Beta-blocker                                       2,075 (77.9)         384 (80.0)          597 (76.9)           0.784
                             ACE inhibitor or ARB                               2,158 (81.0)         383 (79.8)          600 (77.3)           0.079

Values are presented as mean±standard deviation, median (interquartile range) or number (percentage).

ACE = angiotensin-converting enzyme; ARB = angiotensin-II receptor blocker; CK-MB = creatine kinase-myocardial band isoenzyme; CRP = C-reactive protein; HDL = high-density lipoprotein; LDL = low-density lipoprotein; LVEF = left ventricular ejection fraction; NT pro BNP = N-terminal pro B-type natriuretic peptide; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

###### Procedural characteristics

![](kcj-49-419-i002)

  Variables                          Time from admission to statin initiation (hours)   p value                                   
  ---------------------------------- -------------------------------------------------- -------------- ------------- ------------ -------
  Infarct-related artery                                                                                                          
                                     Left anterior descending artery                    1,311 (49.2)   202 (42.1)    361 (46.5)   0.061
                                     Right coronary artery                              882 (33.1)     186 (38.8)    266 (34.3)   0.057
                                     Left circumflex artery                             409 (15.3)     84 (17.5)     137 (17.7)   0.088
                                     Left main coronary artery                          51 (1.9)       8 (1.7)       12 (1.5)     0.475
  Multivessel disease                1,348 (50.6)                                       235 (49.0)     441 (56.8)    0.007        
  ACC/AHA B2/C lesion                2,094 (78.6)                                       369 (76.9)     606 (78.1)    0.648        
  Pre-PCI TIMI flow grade 0          1,161 (45.5)                                       195 (41.8)     282 (38.1)    \<0.001      
  Coronary stenting                  2,617 (98.2)                                       467 (97.3)     759 (97.9)    0.463        
  Total No. of stents                1.66±0.93                                          1.60±0.87      1.71±0.93     0.096        
  Total stent length (mm)            30 (20--49)                                        28 (23--48)    32 (20--51)   0.472        
  Mean stent diameter (mm)           3.21±0.43                                          3.18±0.41      3.18±0.41     0.052        
  Use of intravascular ultrasound    722 (27.1)                                         139 (29.0)     195 (25.1)    0.413        
  Post-PCI TIMI flow grade 3         2,420 (92.6)                                       438 (93.0)     704 (93.4)    0.490        
  Procedural complications                                                                                                        
                                     Periprocedural shock                               62 (2.3)       25 (5.2)      31 (4.0)     0.003
                                     No-reflow phenomenon                               144 (5.4)      27 (5.6)      36 (4.6)     0.462
                                     Ventricular tachycardia or fibrillation            33 (1.2)       11 (2.3)      19 (2.4)     0.010
  Use of intra-aortic balloon pump   100 (3.8)                                          24 (5.0)       42 (5.4)      0.088        
  Thrombi aspiration                 115 (4.3)                                          26 (5.4)       43 (5.5)      0.118        

Values are presented as mean±standard deviation, median (interquartile range) or number (percentage).

ACC = American College of Cardiology; AHA = American Heart Association; PCI = percutaneous coronary intervention; TIMI = thrombolysis in myocardial infarction.

All analyses were two-tailed, and a p value \<0.05 was considered to reflect statistical significance. All statistical analyses were performed using SPSS for Windows (ver. 21.0; SPSS Inc., Chicago, IL, USA) and R software (ver. 2.13.2; R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
=======

Baseline and procedural characteristics
---------------------------------------

Statins were prescribed 48 hours after admission in 19.8% of all patients. Group 3 contained older patients and more females. Although the prevalence of hypertension was highest in group 3, other atherosclerotic risk factors were similarly prevalent among the three groups. The frequency of STEMI was highest in group 1, while group 3 had the most patients with a high Killip class (3 or 4). In laboratory examinations, lipid profiles were comparable among the three groups; however, levels of hsCRP and N-terminal pro B-natriuretic peptide were higher in group 3 than in the other groups. Evidence-based medications were prescribed at similar rates among the three groups ([Table 1](#T1){ref-type="table"}). The frequency of infarct-related artery was comparable among the groups; however, multivessel coronary artery disease was seen most frequently in group 3. There were no differences among the three groups in any other procedural characteristic, except for a higher prevalence of pre-PCI TIMI flow grade 0 in group 1, and a higher frequency of periprocedural cardiogenic shock in group 2 ([Table 2](#T2){ref-type="table"}). Among the three propensity score-matched models, there were no significant differences in baseline or procedural characteristics ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

###### Baseline clinical characteristics in propensity score matched populations according to different statin initiation timing
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  Variables                  Model 1 (group I vs. II or III)   Model 2 (group I or II vs. III)   Model 3 (group I vs. II)                                                                                                                 
  -------------------------- --------------------------------- --------------------------------- -------------------------- ------------ -------------------- -------------------- ------------ -------------------- -------------------- -------
  Demographics                                                                                                                                                                                                                            
                             Age (years)                       62.2±12.5                         62.8±12.3                  0.212        62.6±12.3            63.2±12.4            0.365        61.5±12.4            61.9±12.0            0.536
                             Male                              906 (72.6)                        881 (70.6)                 0.267        545 (71.0)           529 (68.9)           0.373        341 (71.6)           351 (73.7)           0.467
  Initial vital signs                                                                                                                                                                                                                     
                             Systolic BP (mmHg)                130.3±28.5                        128.3±29.0                 0.093        130.1±28.5           127.6±29.9           0.089        128.7±26.9           129.6±27.4           0.635
                             Heart rate (/minute)              76.0±17.9                         76.3±19.8                  0.660        77.0±19.2            76.6±20.3            0.661        75.8±18.5            75.7±18.5            0.853
  Medical history                                                                                                                                                                                                                         
                             Current or ex-smoking             716 (57.4)                        711 (57.0)                 0.840        434 (56.5)           417 (54.3)           0.383        273 (57.4)           294 (61.8)           0.166
                             Hypertension                      617 (49.4)                        647 (51.8)                 0.230        388 (50.5)           404 (52.6)           0.414        250 (52.5)           239 (50.2)           0.476
                             Diabetes mellitus                 382 (30.6)                        403 (32.3)                 0.365        247 (32.2)           250 (32.6)           0.870        155 (32.6)           151 (31.7)           0.781
                             Familial history of CAD           61 (4.9)                          70 (5.6)                   0.419        41 (5.3)             42 (5.5)             0.910        23 (4.8)             28 (5.9)             0.472
                             CKD                               43 (3.4)                          49 (3.9)                   0.524        29 (3.8)             30 (3.9)             0.894        11 (2.3)             16 (3.4)             0.329
                             CVA                               52 (4.2)                          55 (4.4)                   0.767        3 (4.8)              39 (5.1)             0.814        19 (4.0)             16 (3.4)             0.605
                             Previous MI                       48 (3.8)                          42 (3.4)                   0.519        37 (4.8)             30 (3.9)             0.382        8 (1.7)              12 (2.5)             0.366
                             Previous PCI                      49 (3.9)                          44 (3.5)                   0.597        40 (5.2)             30 (3.9)             0.221        9 (1.9)              15 (3.2)             0.215
  STEMI                      712 (57.1)                        677 (54.2)                        0.158                      428 (55.7)   424 (55.2)           0.837                276 (58.0)   252 (52.9)           0.118                
  Killip class ≥3            119 (9.5)                         143 (11.5)                        0.117                      81 (10.5)    101 (13.2)           0.114                43 (9.0)     38 (8.0)             0.561                
  Laboratory findings                                                                                                                                                                                                                     
                             Serum creatinine (mg/dL)          1.0 (0.8--1.2)                    1.0 (0.8--1.2)             0.335        1.0 (0.8--1.2)       1.0 (0.8--1.2)       0.894        0.9 (0.8--1.2)       1.0 (0.8--1.2)       0.834
                             Peak troponin-I (mg/dL)           38 (7--50)                        29 (6--42)                 0.822        38 (7--50)           35 (6--42)           0.545        37 (7--50)           22 (6--42)           0.876
                             Peak CK-MB (mg/dL)                45 (13--126)                      35 (11--104)               0.193        44 (14--141)         39 (12--112)         0.383        44 (12--127)         28 (11--94)          0.052
                             Total cholesterol (mg/dL)         182 (156--207)                    184 (159--207)             0.191        184 (157--208)       182 (157--207)       0.559        182 (157--150)       184 (160--204)       0.325
                             Triglyceride (mg/dL)              103 (71--146)                     110 (77--150)              0.098        107 (74--152)        109 (77--144)        0.786        105 (74--150)        111 (76--156)        0.286
                             HDL-cholesterol (mg/dL)           42 (36--48)                       41 (35--48)                0.132        42 (36--48)          41 (35--48)          0.648        42 (37--48)          41 (36--48)          0.900
                             LDL-cholesterol (mg/dL)           115 (95--140)                     118 (97--139)              0.179        118 (96--142)        116 (96--139)        0.696        116 (95--140)        119 (99--139)        0.275
                             Serum glucose (mg/dL)             151 (120--186)                    151 (119--196)             0.322        151 (118--193)       152 (121--200)       0.880        150 (118--187)       148 (113--192)       0.616
                             NT pro BNP (pg/mL)                1,643 (248--2,270)                2,157 (369--2,270)         0.096        1,969 (311--2,270)   2,270 (471--2,270)   0.668        1,779 (229--2,270)   1,283 (279--2,270)   0.895
                             hsCRP (mg/L)                      7.6 (2.2--21.8)                   11.9 (3.0--24.3)           0.089        6.8 (1.9--21.8)      13.9 (3.5--24.6)     0.104        7.9 (2.3--21.8)      8.3 (2.5--23.2)      0.929
  LVEF (%)                   54.5±11.1                         54.2±11.8                         0.594                      53.4±11.5    53.2±11.6            0.764                55.3±10.8    55.9±11.7            0.330                
  Medications at discharge                                                                                                                                                                                                                
                             Aspirin                           1,248 (100)                       1,248 (100)                1.000        768 (100)            768 (100)            1.000        475 (99.8)           475 (99.8)           1.000
                             Clopidogrel                       1,244 (99.7)                      1,245 (99.8)               0.705        763 (99.3)           765 (99.6)           0.478        476 (100)            476 (100)            1.000
                             Beta-blocker                      977 (78.3)                        974 (78.0)                 0.884        595 (77.5)           592 (77.1)           0.855        381 (80.0)           380 (79.8)           0.935
                             ACE inhibitor or ARB              1,004 (80.4)                      975 (78.1)                 0.152        617 (80.3)           596 (77.6)           0.189        377 (79.2)           379 (79.6)           0.873

ACE = angiotensin-converting enzyme; ARB = angiotensin-II receptor blocker; BP = blood pressure; CAD = coronary artery disease; CK-MB = creatine kinase-myocardial band isoenzyme; CKD = chronic kidney disease; CVA = cerebrovascular accident; HDL = high-density lipoprotein; hsCRP = high-sensitivity C-reactive protein; LDL = low-density lipoprotein; LVEF = left ventricular ejection fraction; MI = myocardial infarction; NT pro BNP = N-terminal pro B-type natriuretic peptide; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

###### Procedural characteristics in propensity score matched populations according to different statin initiation timing

![](kcj-49-419-i004)

  Variables                  Model 1 (group I vs. II or III)   Model 2 (group I or II vs. III)   Model 3 (group I vs. II)                                                                                     
  -------------------------- --------------------------------- --------------------------------- -------------------------- ------------- ------------- ------------ ------------- ------------- ------------ -------
  Infarct-related artery                                                                                                                                                                                      
                             Left anterior descending          573 (45.9)                        559 (44.8)                 0.572         352 (45.8)    357 (46.5)   0.798         217 (45.6)    199 (41.8)   0.240
                             Right coronary artery             445 (35.7)                        449 (36.0)                 0.867         264 (34.4)    263 (34.2)   0.957         180 (37.8)    185 (38.9)   0.739
                             Left circumflex artery            208 (16.7)                        220 (17.6)                 0.524         135 (17.6)    136 (17.7)   0.947         72 (15.1)     84 (17.6)    0.293
                             Left main coronary artery         22 (1.8)                          20 (1.6)                   0.756         17 (2.2)      12 (1.6)     0.349         7 (1.5)       8 (1.7)      0.795
  Multivessel disease        671 (53.8)                        672 (53.8)                        0.968                      411 (53.5)    435 (56.6)    0.218        230 (48.3)    234 (49.2)    0.795        
  ACC/AHA B2/C lesion        972 (77.9)                        969 (77.6)                        0.885                      607 (79.0)    599 (78.0)    0.619        368 (77.3)    366 (76.9)    0.877        
  Pre-PCI TIMI flow 0        510 (40.9)                        475 (38.1)                        0.152                      301 (39.2)    281 (36.6)    0.293        217 (45.6)    194 (40.8)    0.132        
  Coronary stenting          1,219 (97.7)                      1,221 (97.8)                      0.787                      753 (98.0)    753 (98.0)    1.000        465 (97.7)    463 (97.3)    0.679        
  Total No. of stents        1.69±0.94                         1.67±0.90                         0.645                      1.70±0.94     1.71±0.92     0.854        1.58±0.86     1.60±0.87     0.625        
  Total stent length (mm)    31 (23--48)                       30 (23--49)                       0.473                      30 (20--49)   32 (21--51)   0.924        28 (20--47)   28 (23--48)   0.762        
  Mean stent diameter (mm)   3.19±0.39                         3.18±0.41                         0.240                      3.19±0.39     3.18±0.42     0.860        3.18±0.41     3.18±0.41     0.900        
  Use of IVUS                323 (25.9)                        332 (26.6)                        0.682                      201 (26.2)    194 (25.3)    0.683        141 (29.6)    137 (28.8)    0.776        
  Post-PCI TIMI flow 3       1,175 (94.2)                      1,165 (93.3)                      0.408                      717 (93.4)    719 (93.6)    0.836        448 (94.1)    443 (93.1)    0.508        
  Procedural complications                                                                                                                                                                                    
                             Periprocedural shock              39 (3.1)                          54 (4.3)                   0.113         22 (2.9)      29 (3.8)     0.319         16 (3.4)      25 (5.3)     0.151
                             No-reflow phenomenon              65 (5.2)                          62 (5.0)                   0.785         36 (4.7)      36 (4.7)     1.000         22 (4.6)      27 (5.7)     0.463
                             VT or VF                          22 (1.8)                          29 (2.3)                   0.322         14 (1.8)      16 (2.1)     0.712         7 (1.5)       10 (2.1)     0.463
  Use of IABP                54 (4.3)                          65 (5.2)                          0.301                      31 (4.0)      37 (4.8)      0.457        19 (4.0)      24 (5.0)      0.435        
  Thrombi aspiration         60 (4.8)                          68 (5.4)                          0.468                      29 (3.8)      43 (5.6)      0.091        23 (4.8)      25 (5.3)      0.767        

Values are presented as mean±standard deviation, median (interquartile range) or number (percentage).

ACC = American College of Cardiology; AHA = American Heart Association; IABP = intra-aortic balloon pump; IVUS = intravascular ultrasound; PCI = percutaneous coronary intervention; TIMI = thrombolysis in myocardial infarction; VF = ventricular fibrillation; VT = ventricular tachycardia.

Clinical outcomes
-----------------

In model 1 (\<24 hours vs. ≥24 hours), more MACE occurred in the early statin group (\<24 hours) (14.3% vs. 18.4%, adjusted hazard ratio \[HR\], 0.77; 95% confidence interval \[CI\], 0.66--0.91; p=0.002). Early statin was also associated with lower incidence rates of nonfatal spontaneous MI, TVR and stent thrombosis. Results were similar in model 2 (\<48 hours vs. ≥48 hours). Statin initiation \<48 hours reduced MACE (14.6% vs. 19.7%, adjusted HR, 0.81; 95% CI, 0.67--0.97; p=0.022), cardiac death and nonfatal spontaneous MI compared to statin initiation at a later time. However, there were no differences in the incidence of MACE (14.3% vs. 16.3%, adjusted HR, 0.87; 95% CI, 0.68--1.11; p=0.268) or other secondary endpoints between the early (\<24 hours) and later statin initiation (24--48 hours) groups in model 3 ([Table 5](#T5){ref-type="table"}).

###### Clinical outcomes according to different statin initiation timing
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  Variables                         Time (hours)                            Unadjusted HR    Adjusted HR   Propensity-score-adjusted HR                                                                               
  --------------------------------- --------------------------------------- ---------------- ------------- ------------------------------ ------------------- ------- ------------------- ------- ------------------- -------
  Model 1 (group I vs. II or III)                                                                                                                                                                                     
                                    Cardiac death, MI or TVR                381 (14.3)       231 (18.4)    0.001                          0.75 (0.64--0.88)   0.001   0.77 (0.66--0.91)   0.002   0.78 (0.64--0.94)   0.011
                                    All-cause death                         356 (13.4)       201 (16.0)    0.027                          0.81 (0.68--0.96)   0.017   0.87 (0.73--1.08)   0.108   0.87 (0.71--1.07)   0.179
                                    Cardiac death                           115 (4.3)        74 (5.9)      0.032                          0.71 (0.53--0.95)   0.021   0.79 (0.59--1.06)   0.115   0.74 (0.52--1.05)   0.090
                                    Nonfatal spontaneous MI                 52 (2.0)         41 (3.3)      0.012                          0.59 (0.39--0.89)   0.011   0.60 (0.40--0.91)   0.015   0.48 (0.28--0.82)   0.007
                                    TLR                                     215 (8.1)        121 (9.6)     0.102                          0.82 (0.65--1.02)   0.074   0.82 (0.66--1.03)   0.082   0.82 (0.63--1.07)   0.137
                                    TVR                                     262 (9.8)        150 (11.9)    0.044                          0.80 (0.66--0.98)   0.031   0.81 (0.66--0.99)   0.036   0.83 (0.65--1.05)   0.122
                                    Non-TVR                                 155 (5.8)        80 (6.4)      0.496                          0.90 (0.69--1.18)   0.439   0.90 (0.69--1.18)   0.456   0.96 (0.71--1.32)   0.812
                                    Stroke                                  55 (2.1)         34 (2.7)      0.207                          0.75 (0.49--1.15)   0.184   0.76 (0.49--1.17)   0.207   0.69 (0.41--1.16)   0.164
                                    Definite or probable stent thrombosis   72 (2.7)         49 (3.9)      0.043                          0.68 (0.47--0.98)   0.037   0.69 (0.48--0.99)   0.045   0.51 (0.31--0.83)   0.006
  Model 2 (group I or II vs. III)   \<48 (n=3,145)                          ≥48 (n=776)                                                                                                                               
                                    Cardiac death, MI or TVR                459 (14.6)       153 (19.7)    \<0.001                        0.72 (0.60--0.87)   0.001   0.81 (0.67--0.97)   0.022   0.69 (0.54--0.89)   0.005
                                    All-cause death                         425 (13.5)       132 (17.0)    0.012                          0.78 (0.64--0.95)   0.012   0.87 (0.72--1.06)   0.173   0.89 (0.69--1.15)   0.363
                                    Cardiac death                           135 (4.3)        54 (7.0)      0.002                          0.60 (0.44--0.83)   0.002   0.72 (0.52--0.99)   0.042   0.74 (0.49--0.98)   0.047
                                    Nonfatal spontaneous MI                 65 (2.1)         28 (3.6)      0.011                          0.57 (0.37--0.89)   0.014   0.59 (0.38--0.92)   0.021   0.47 (0.24--0.91)   0.024
                                    TLR                                     257 (8.2)        79 (10.2)     0.073                          0.79 (0.61--1.02)   0.065   0.79 (0.61--1.02)   0.074   0.69 (0.49--0.98)   0.039
                                    TVR                                     319 (10.1)       93 (12.0)     0.134                          0.84 (0.66--1.05)   0.127   0.84 (0.67--1.06)   0.141   0.72 (0.52--0.98)   0.039
                                    Non-TVR                                 180 (5.7)        55 (7.1)      0.152                          0.80 (0.59--1.08)   0.150   0.84 (0.67--1.06)   0.141   1.05 (0.72--1.52)   0.815
                                    Stroke                                  69 (2.2)         20 (2.6)      0.521                          0.85 (0.52--1.40)   0.531   0.87 (0.53--1.44)   0.598   0.86 (0.45--1.65)   0.651
                                    Definite or probable stent thrombosis   91 (2.9)         30 (3.9)      0.161                          0.74 (0.49--1.12)   0.159   0.76 (0.50--1.15)   0.194   0.56 (0.31--1.02)   0.059
  Model 3 (group I vs. II)          \<24 (n=2,665)                          24--48 (n=480)                                                                                                                            
                                    Cardiac death, MI or TVR                381 (14.3)       78 (16.3)     0.264                          0.84 (0.66--1.07)   0.160   0.87 (0.68--1.11)   0.268   0.84 (0.61--1.16)   0.290
                                    All-cause death                         356 (13.4)       69 (14.4)     0.549                          0.90 (0.69--1.16)   0.402   0.89 (0.69--1.15)   0.368   0.94 (0.67--1.32)   0.723
                                    Cardiac death                           115 (4.3)        20 (4.2)      0.883                          1.00 (0.62--1.61)   0.997   0.99 (0.61--1.59)   0.953   1.06 (0.57--1.95)   0.856
                                    Nonfatal spontaneous MI                 52 (2.0)         13 (2.7)      0.283                          0.69 (0.38--1.27)   0.237   0.67 (0.37--1.24)   0.203   0.45 (0.17--1.19)   0.107
                                    TLR                                     215 (8.1)        42 (8.8)      0.615                          0.89 (0.64--1.24)   0.500   0.94 (0.67--1.31)   0.697   0.94 (0.61--1.45)   0.775
                                    TVR                                     262 (9.8)        57 (11.9)     0.172                          0.79 (0.59--1.06)   0.116   0.82 (0.61--1.09)   0.177   0.80 (0.55--1.18)   0.269
                                    Non-TVR                                 155 (5.8)        25 (5.2)      0.598                          1.09 (0.72--1.67)   0.683   1.07 (0.70--1.64)   0.756   0.99 (0.57--1.73)   0.974
                                    Stroke                                  55 (2.1)         14 (2.9)      0.240                          0.68 (0.38--1.22)   0.196   0.68 (0.38--1.22)   0.190   0.77 (0.35--1.70)   0.517
                                    Definite or probable stent thrombosis   72 (2.7)         19 (4.0)      0.131                          0.66 (0.39--1.10)   0.108   0.65 (0.39--1.09)   0.100   0.57 (0.27--1.20)   0.136

Propensity-score adjusted HRs were calculated in 1,248 matched pair in model 1, 767 matched pair in model 2, and 475 matched pair in model 3.

CI = confidence interval; HR = hazard ratio; MI = myocardial infarction; TLR = target-lesion revascularization; TVR = target-vessel revascularization.

Results were comparable after propensity score-matching ([Table 5](#T5){ref-type="table"}). Early statin initiation (\<24 hours) was associated with lower cumulative incidences of MACE (propensity-score adjusted HR, 0.78; 95% CI, 0.64--0.95; p=0.011, [Figure 1A](#F1){ref-type="fig"}), nonfatal spontaneous MI and stent thrombosis in model 1. In model 2, MACE also occurred less frequently in the early statin initiation \<48 hours group (propensity-score adjusted HR, 0.69; 95% CI, 0.54--0.89; p=0.005, [Figure 1B](#F1){ref-type="fig"}); similar results were seen in nonfatal spontaneous MI, TLR and TVR. There was no significant difference in MACE incidence (propensity-score adjusted HR, 0.84; 95% CI, 0.61--1.16; p=0.290, [Figure 1C](#F1){ref-type="fig"}) or other secondary outcomes between the early (\<24 hours) and later statin initiation (24--48 hours) groups in model 3 following propensity score-matching.

![Kaplan-Meier curves for cumulative incidence of cardiac death, myocardial infarction or TVR in patients who received statin \<24 hours vs. ≥24 hours (A), \<48 hours vs. ≥48 hours (B), and \<24 hours vs. 24--48 hours (C) after admission.\
AMI = acute myocardial infarction; MI = myocardial infarction; TVR = target-vessel revascularization.](kcj-49-419-g001){#F1}

Subgroup analysis and independent predictors of delay of statin initiation ≥48 hours after admission
----------------------------------------------------------------------------------------------------

Subgroup analysis of propensity score-matched populations in model 2 was performed ([Figure 2](#F2){ref-type="fig"}). The subgroups showed similar rates of MACE, and did not significantly interact with the early statin initiation \<48 hours group. We also performed multivariate logistic regression analysis to identify independent predictors of delayed statin initiation (≥48 hours) using variables that had a p\<0.05 in the univariate analysis ([Table 6](#T6){ref-type="table"}). Among these variables, female gender and Killip class 3 or 4 were identified as independent predictors of delayed statin initiation. On the contrary, statins were prescribed earlier in patients with STEMI.

![Subgroup analysis of major adverse cardiac events in model 2 (\<48 hours vs. ≥48 hours).\
CI = confidence interval; DM = diabetes mellitus; GFR = glomerular filtration rate; LAD = left anterior descending; LCX = left circumflex; LM = left main; LVEF = left ventricular ejection fraction; NSTEMI = non-ST-segment elevation myocardial infarction; RCA = right coronary artery; STEMI = ST-segment elevation myocardial infarction.](kcj-49-419-g002){#F2}

###### Independent predictors of delay of statin initiation ≥48 hours after admission
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  Variables                                           OR (95% CI)         p value
  --------------------------------------------------- ------------------- ---------
  Age ≥65 years                                       1.16 (0.98--1.37)   0.089
  Female                                              1.22 (1.02--1.47)   0.032
  History of cerebrovascular accident                 1.67 (0.93--3.03)   0.089
  Killip class 3 or 4                                 1.61 (1.25--2.07)   \<0.001
  Chronic kidney disease or end-stage renal disease   1.23 (0.82--1.84)   0.328
  STEMI                                               0.71 (0.61--0.83)   \<0.001
  Development of procedural complications             1.21 (0.89--1.64)   0.223

Procedural complications include periprocedural shock, no-reflow phenomenon, or ventricular arrhythmia.

CI = confidence interval; OR = odds ratio; STEMI = ST-segment elevation myocardial infarction.

DISCUSSION
==========

The main purpose of the present study was to explore the impact of the timing of statin initiation on long-term clinical outcomes in statin-naïve patients with AMI. Our principal findings were as follows: 1) approximately 20% of statin-naïve patients with AMI received a statin after 48 hours following admission; and 2) early statin initiation within 48 hours after admission could reduce long-term adverse cardiac events, including cardiac death, nonfatal MI, TLR and TVR compared to statin initiation at a later time. This study provides important insights into the long-term outcomes of AMI patient through the utilization of a multi-center registry that reflects real-life practice.

The current clinical guidelines do not specify the optimal timing for statin initiation in AMI patients after admission.[@B1][@B2][@B3][@B4] This could be due to the heterogeneity of the timing of statin initiation in previous studies, and to the lack of randomized trials on this topic. In fact, several small single-center retrospective studies reported no significant difference in outcomes regarding the timing of statin initiation.[@B5][@B6] One study indicated that early statin initiation (within 2 days after admission) does not reduce adverse cardiac outcomes, and concluded that in-hospital statin initiation is sufficient for treating patients with acute coronary syndrome.[@B6] In contrast, in the large-scale study using the National Registry of Myocardial Infarction 4 database, early statin therapy (within 24 hours of hospitalization) for AMI was associated with a significantly lower rate of in-hospital mortality.[@B7] Using the Euro Heart Survey registry, Lenderink et al.[@B9] also showed that early statin therapy (within 24 hours after admission) in 8,000 STEMI patients was associated with reduced 1-month mortality. Although they demonstrated the efficacy of early statin therapy (within 24 hours of hospitalization) in the treatment of AMI patients, their study focused only on short-term cardiovascular outcomes. In the current study, we showed that early statin therapy (within 48 hours after admission) was associated with a lower incidence of MACE in the long-term compared to later statin initiation (\> 48 hours after admission). In our cohort, almost 20% of statin-naïve patients with AMI received a statin within 48 hours after admission. Independent predictors of delayed statin initiation after 48 hours were female gender and Killip class 3 or 4. However, no evidence indicates a delay in statin therapy in female or unstable patients, such as those experiencing cardiogenic shock. Although AMI cases complicated by cardiogenic shock may show higher levels of liver enzymes, we suggest that statins should be prescribed for all AMI patients as early as possible, unless there is a contraindication. In Korea, both the statin non-prescription rate during hospitalisation and the discontinuation rate after discharge remain high in patients with AMI.[@B13][@B16] Therefore, education emphasizing the importance of early statin therapy is needed for both medical teams and patients. Furthermore, we believe that criteria for deciding the optimal timing of statin initiation should be implemented to increase the statin prescription rate in the acute setting.

Numerous factors related to statins can affect clinical outcomes in patients with AMI. These include statin intensity,[@B17] dosage,[@B18] timing, concentration of low-density lipoprotein[@B19][@B20] and patient status. However, the mechanism by which early statin initiation (within 48 hours after admission) confers benefits for statin-naïve patients with AMI is unclear. In one study, late statin initiation (48 hours after admission in STEMI patients) produced a milder attenuation of inflammation burst compared to early statin initiation (i.e., on admission).[@B21] This finding suggests that the timing of statin therapy during AMI may be a key determinant of its clinical benefits. Many pleiotropic effects of statins aside from reducing low-density lipoprotein, such as plaque stabilization, improvement of endothelial dysfunction, decreased thrombogenicity, and reduced inflammation, could affect patient outcomes.[@B22] These effects can be achieved when statin therapy is initiated as early as possible after MI. PCI timing in our study may also have influenced the endpoints, as all patients in our cohort received PCI within 48 hours after admission; therefore, not all patients received a pre-procedural statin. However, controversy exists as to whether pre-procedural statin use is associated with in-hospital or long-term complications. Moreover, most studies on pre-procedural statin treatment focused on stable coronary artery disease, not AMI.[@B23][@B24][@B25] However, there were 3 studies which investigated the clinical impact of pre-procedural statin use and pre-procedural high-dose statin in patients with acute coronary syndrome. Although these studies showed the clinical benefits, improved microvascular myocardial perfusion and reducing infarct size by pre-procedural statin in patients with acute coronary syndrome, they only focused on the pre-procedural statin, not a timing of statin initiation.[@B26][@B27][@B28] More investigations utilizing larger real-world registries and randomized designs are needed to further explore this issue.

The current study has several limitations. First, this study used a non-randomised, observational design, despite being based on a large, multi-center registry, which resulted in differences in baseline clinical and angiographic findings among the groups. Although we performed propensity-matched analysis of stratified groups, other variables not included in our registry may also have influenced the study outcomes. Second, data on dosage and type of statin, as well as patient compliance, were not considered. Unfortunately, there was no exact information about statin dosages and types in our registry. There is a possibility that statin dosage, type and compliance might affect clinical outcomes, although this remains controversial. There was a study which investigated the impact of statin intensity in Korean AMI patients using the Korean Acute Myocardial Infarction Registry, and high-intensity statin therapy did not show clinical benefits over low-to-moderate intensity statin therapy after AMI.[@B29] Although this issue needs more study results, the impact of statin intensity in Korean AMI patients should be compared to those in western AMI patients. Third, all patients in the current study received clopidogrel as a P2Y12 inhibitor instead of potent P2Y12 inhibitors such as prasugrel or ticagrelor because of study period. The current registry registered patients between 2004 and 2009, therefore it is not available to prescribe prasugrel or ticagrelor in the market. Finally, we could not perform a serial check of the laboratory findings within the registry, and therefore inflammatory state and post-procedural myocardial necrosis data were not examined.

In conclusion, the timing of statin therapy initiation is an important factor in patient outcomes in the case of AMI. This study was not a randomised controlled trial and the timing of statin initiation was at the discretion of individual operators. Using a large, real-world registry, we found that early statin therapy (within 48 hours after admission) reduced long-term clinical adverse events in statin-naïve patients with AMI compared to later statin initiation. While we support the current guidelines on early statin initiation in AMI patients, we propose that initiation \<48 hours after admission could represent the optimal timing for statin therapy.
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